PMI and BAT Resolve Intellectual Property Dispute

BATPMI by 2FIRSTS.ai
Feb.03.2024
PMI and BAT Resolve Intellectual Property Dispute
Philip Morris International (PMI) and British American Tobacco (BAT) have resolved their intellectual property dispute over heated tobacco and e-cigarette products.

On February 2nd, in the Eastern Time Zone of the United States, both Philip Morris International (PMI) and British American Tobacco (BAT) announced on their respective official websites that they have resolved their intellectual property dispute regarding heated tobacco and e-cigarette products.

 

PMI and BAT Resolve Intellectual Property Dispute
PMI Press Release | Image Source: PMI Official Website

 

British American Tobacco (BAT) and Philip Morris International (PMI) have announced a settlement agreement that includes non-monetary terms between the two companies. This agreement resolves all ongoing global patent infringement lawsuits, including any related injunctions and exclusions, and prevents future claims against current heated tobacco and vaping products. The settlement also allows both parties to continue innovating and launching improved versions of their products. Both companies are committed to ongoing innovation in the reduced-risk product space, furthering efforts to reduce the harm caused by tobacco.

 

PMI and BAT Resolve Intellectual Property Dispute
BAT News Just In | Image Source: BAT Official Website.

 

These two international tobacco companies have been embroiled in a multifaceted patent war. BAT's e-cigarette brand VUSE and heat-not-burn tobacco device brand GLO suffered a defeat in one case, being ordered to pay millions of dollars; while PMI was prohibited from introducing its flagship heat-not-burn tobacco device IQOS into the United States due to another lawsuit.

 

PMI CEO, Jacek Olczak, expressed satisfaction with the resolution, stating, "We are pleased that both parties are content with the outcome. Adult smokers worldwide consistently display a desire for a range of smoke-free products, and we believe that continued innovation in reduced-risk alternatives can expedite the reduction of smoking-related harms, benefiting consumers and public health as a whole. Meanwhile, we will remain committed to phasing out the sale of traditional cigarettes as part of PMI's journey.

 

BAT CEO Tadeu Marroco has expressed his satisfaction with the recent agreement, stating, "This agreement is a significant step forward for BAT and all our stakeholders. With the successful development of our billion-pound brands VUSE and GLO, the potential for reducing tobacco harm is evident. I am pleased that this settlement will allow BAT to focus on developing innovative solutions to provide adult consumers with reduced-risk products and contribute to our 'A Better Tomorrow' mission. By doing so, we will help build a smoke-free world for consumers, investors, and society as a whole."

 

2FIRSTS has invited Chinese e-cigarette legal expert Counsellor Tang Shunliang to provide a professional analysis of the background and potential impact of the patent settlement between PMI and BAT. An article providing this analysis will be published later. Stay tuned.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Center for Tobacco Products Acting Director Bret Koplow issued a statement on May 7 outlining new steps to accelerate tobacco product premarket application review. The statement said CTP reduced the backlog of applications by approximately 70% in 2025 and that there is no longer a queue for PMTAs pending acceptance review.
May.09 by 2FIRSTS.ai
PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI’s U.S. business released a white paper and cited a national online survey showing that 79.00% of Americans surveyed believe more should be done to reduce smoking-related harm. The paper calls on policymakers, public health authorities, and medical professionals to place cigarette smoking back at the center of public health priorities, and recommends broader access to FDA-authorized smoke-free alternatives, clearer nicotine risk communication, and risk-based taxation.
Apr.15 by 2FIRSTS.ai
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal is among the countries opposing the UK Tobacco and Vapes Bill, which would ban tobacco sales to people born on or after Jan. 1, 2009. According to the report, Portugal, Croatia, the Czech Republic, Greece, Italy, Slovakia and Romania have submitted reasoned opinions and formal observations to Brussels, arguing that the bill breaches post-Brexit arrangements including the Windsor Framework.
Apr.24 by 2FIRSTS.ai
Imperial Brands to Close Langenhagen Cigarette Factory by 2027
Imperial Brands to Close Langenhagen Cigarette Factory by 2027
Imperial Brands said it will gradually close the Reemtsma factory in Langenhagen near Hanover by 2027 after efforts to find a buyer failed to produce a sustainable agreement. The factory has produced cigarettes since 1971 and currently affects around 600 employees. The company said it had examined all realistic options over recent months but did not receive a binding offer from a potential buyer.
Mar.27 by 2FIRSTS.ai
The new regulations on nicotine in Argentina are creating caution, expectations, and doubts about the market, according to a local reference in harm reduction for smoking.
The new regulations on nicotine in Argentina are creating caution, expectations, and doubts about the market, according to a local reference in harm reduction for smoking.
The new Argentine framework for tobacco and nicotine marks a shift from prohibition towards registration, traceability, and health surveillance. Juan Facundo Teme told 2Firsts that adult consumers and some of the commercial sector are cautiously optimistic, although concerns remain about flavors, registration costs, and market access.
May.11
FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02